All In Biotech

Drug Trial Radar · NCT06428487

Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer

Phase II,Open-label, Non-randomized Study of Neoadjuvant Prolgolimab Monotherapy in Patients With Locally Advanced Colorectal Cancer With Microsatellite Instability (MSI)/Mismatch Repair (dMMR) Deficiency

Last checked: Nov 20, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Mar 31, 2022

Primary completion

Dec 31, 2024

Study completion Jun 30, 2025

Sponsor

Lead sponsor
Blokhin's Russian Cancer Research CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this phase II study patients with stage II-III MSI/dMMR colorectal adenocarcinoma with no signs of distant metastases will be treated with immunotherapy (prolgolimab). The duration of treatment is 6 months (12 cycles)

Conditions

  • Colorectal Cancer

Interventions

  • ProlgolimabDrug

    Prolgolimab infusions 1 mg/kg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathological complete response (pCR)Time frame: up to 8 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • N.N. Blokhin NMRCO

    Moscow, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.